Long-Term Safety and Efficacy of Tacrolimus in Myasthenia Gravis
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: Myasthenia gravis (MG) is a lifelong autoimmune disorder that affects neuromuscular transmission. The long-termtreatment plan should include immunotherapy. We investigated the long-term safety and efficacy of tacrolimus for the treatmentof MG in real-world clinical practice. Materials and Methods: We retrospectively reviewed 160 MG patients treated with tacrolimus from 2005 to 2015. MyastheniaGravis Foundation of America (MGFA) clinical classification, MGFA post-intervention status, myasthenic functional score, anddose of oral prednisolone were investigated. Results: Adverse events occurred in 68 patients (42.5%), most of which were minor and well-managed. Clinical severity scales improvedafter administration of tacrolimus, compared to the baseline. Compared to 6 months before administration of tacrolimus,prednisolone dose significantly decreased at 12 months after treatment (2.85±0.92 mg/day, p=0.002), 18 months after treatment(3.36±0.99 mg/day, p=0.001), and 24 months after treatment (3.71±0.93 mg/day, p<0.001). Conclusion: Tacrolimus may be effective in reducing the severity of MG and may permit a reduction in the steroid dose prescribedto the patients. Adverse events due to tacrolimus treatment were not serious.
Abstract
Purpose: Myasthenia gravis (MG) is a lifelong autoimmune disorder that affects neuromuscular transmission. The long-termtreatment plan should include immunotherapy. We investigated the long-term safety and efficacy of tacrolimus for the treatmentof MG in real-world clinical practice. Materials and Methods: We retrospectively reviewed 160 MG patients treated with tacrolimus from 2005 to 2015. MyastheniaGravis Foundation of America (MGFA) clinical classification, MGFA post-intervention status, myasthenic functional score, anddose of oral prednisolone were investigated. Results: Adverse events occurred in 68 patients (42.5%), most of which were minor and well-managed. Clinical severity scales improvedafter administration of tacrolimus, compared to the baseline. Compared to 6 months before administration of tacrolimus,prednisolone dose significantly decreased at 12 months after treatment (2.85±0.92 mg/day, p=0.002), 18 months after treatment(3.36±0.99 mg/day, p=0.001), and 24 months after treatment (3.71±0.93 mg/day, p<0.001). Conclusion: Tacrolimus may be effective in reducing the severity of MG and may permit a reduction in the steroid dose prescribedto the patients. Adverse events due to tacrolimus treatment were not serious.
참고문헌 (24)
- Lewis RA, "Myasthenia gravis: immunological mechanisms and immunotherapy", Ann Neurol, 37(Suppl 1), pp.S51~62 (1995)
- Meriggioli MN, "Autoimmune myasthenia gravis : emerging clinical and biological heterogeneity", Lancet Neurol, 8, pp.475~490 (2009)
- Carr AS, "A systematic review of population based epidemiological studies in Myasthenia Gravis", BMC Neurol, 10, pp.46~ (2010)
- 김승민, "The Epidemiology of Myasthenia Gravis in Korea", Yonsei Medical Journal, 57(2), pp.419~425 (2016), 연세대학교의과대학[DOI]
- Grob D, "Lifetime course of myasthenia gravis", Muscle Nerve, 37, pp.141~149 (2008)
- Schreiber SL, "The mechanism of action of cyclosporin A and FK506", Immunol Today, 13, pp.136~142 (1992)
- Kino T, "FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics", J Antibiot (Tokyo), 40, pp.1249~1255 (1987)
- Kino T, "FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro", J Antibiot(Tokyo), 40, pp.1256~1265 (1987)
- Evoli A, "Successful treatment of myasthenia gravis with tacrolimus", Muscle Nerve, 25, pp.111~114 (2002)
- Konishi T, "Japanese FK506 MG Study Group. Clinical study of FK506 in patients with myasthenia gravis", Muscle Nerve, 28, pp.570~574 (2003)
- Konishi T, "Long-term treatment of generalised myasthenia gravis with FK506(tacrolimus)", J Neurol Neurosurg Psychiatry, 76, pp.448~450 (2005)
- Nagane Y, "Efficacy of low-dose FK506 in the treatment of Myasthenia gravis--a randomized pilot study", Eur Neurol, 53, pp.146~150 (2005)
- Ponseti JM, "Benefits of FK506(tacrolimus)for residual, cyclosporin-and prednisone-resistant myasthenia gravis : one-year follow-up of an openlabel study", Clin Neurol Neurosurg, 107, pp.187~190 (2005)
- Ponseti JM, "Long-term results of tacrolimus in cyclosporine-and prednisone-dependent myasthenia gravis", Neurology, 64, pp.1641~1643 (2005)
- Ponseti JM, "Experience with starting tacrolimus postoperatively after transsternal extended thymectomy in patients with myasthenia gravis", Curr Med Res Opin, 22, pp.885~895 (2006)
- Shimojima Y, "Tacrolimus in refractory patients with myasthenia gravis : coadministration and tapering of oral prednisolone", J Clin Neurosci, 13, pp.39~44 (2006)
- Tada M, "Long-term therapeutic efficacy and safety of low-dose tacrolimus(FK506)for myasthenia gravis", J Neurol Sci, 247, pp.17~20 (2006)
- Nagaishi A, "Long-term treatment of steroiddependent myasthenia gravis patients with low-dose tacrolimus", Intern Med, 47, pp.731~736 (2008)
- Yoshikawa H, "Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis", J Neurol Neurosurg Psychiatry, 82, pp.970~977 (2011)
- Zhao CB, "Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis", Int Immunopharmacol, 11, pp.519~524 (2011)
- Cruz JL, "The emerging role of tacrolimus in myasthenia gravis", Ther Adv Neurol Disord, 8, pp.92~103 (2015)
- Ahn SW, "A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravis", J Neurol Sci, 379, pp.271~275 (2017)
- Jaretzki A 3rd, "Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America", Ann Thorac Surg, 70, pp.327~334 (2000)
- Myasthenia Gravis Clinical Study Group, "A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysi", J Neurol Neurosurg Psychiatry, 56, pp.1157~1163 (1993)